Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology firm Genstruct has entered into a master research agreement with Pfizer designed to cover current and future collaborations.
Subscribe to our email newsletter
The first collaboration under this new agreement is in the area of preclinical drug safety, focusing initially on a systems biology analysis of underlying mechanisms of drug-induced liver injury.
Keith Elliston, president and CEO of Genstruct, said: “This extended relationship with Pfizer provides for the continued application of our systems biology technology to Pfizer’s R&D programs to better predict potential drug toxicities prior to testing of new medicines in humans.”